SWOG clinical trial number
S1900K
A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
18% Accrual
Accrual
18%
Open
Phase
18% Accrual
Accrual
18%
Abbreviated Title
Targeted Treatment for Advanced NSCLC that has a MET Exon 14 Skipping Gene Change
Status Notes
S1900K will open to accrual December 18, 2023, effective 3:00 p.m. EST.
Activated
12/18/2023
Participants
US INSTITUTIONS ONLY
Research committees
LungMAP
Treatment
Ramucirumab
Tepotinib
Patient Study Materials
Patient Clinical Trial Summary
Download PDF of Patient Clinical Trial Summary
Other Study Materials
Eligibility Criteria Expand/Collapse
Other Clinical Trials
S1800E
SWOG Clinical Trial Number
Research Committee(s)
LungMAP
Lung Cancer
Activated
04/28/2025
2% Accrual
Accrual
2%
Open
Phase
S1900J
SWOG Clinical Trial Number
Research Committee(s)
LungMAP
Activated
09/27/2024
2% Accrual
Accrual
2%
Open
Phase
S1900K
SWOG Clinical Trial Number
Research Committee(s)
LungMAP
Activated
12/18/2023
18% Accrual
Accrual
18%
Open
Phase